论文部分内容阅读
目的：探讨ＣＡ１５－３在乳腺癌临床应用价值。方法：ＣＡ１５－３试剂盒购自瑞典ＣａｎＡｇ公司，严格按说明书操作，实验批内批间误差符合要求。对乳腺癌和乳腺良病变各３０例进行观察。结果：乳腺癌患者血清ＣＡ１５－３值为８２．２±１４８ｕ／ｍｌ。明显高于乳腺良性病变患者即９．８±４．９ｕ／ｍｌ。两者之间有显著性差异（Ｐ＜０．０５）。乳腺癌手术前后ＣＡ１５－３值及术前有无腋窝淋巴结转移ＣＡ１５－３值进行比较，发现亦有显著性差异（Ｐ＜０．０５）。结论：ＣＡ１５－３检测在乳腺癌的诊断，有无转移和疗效判断及监测复发方面均有其临床应用价值。
Objective: To investigate the clinical application of CA15-3 in breast cancer. Methods: The CA15-3 kit was purchased from CanAg, Sweden. It was operated strictly in accordance with the instructions. The intra-assay and intra-assay errors met the requirements. Each of 30 cases of breast cancer and breast benign lesions were observed. Results: The serum CA15-3 value of breast cancer patients was 82.2±148u/ml. Significantly higher than patients with benign breast lesions 9.8 ± 4.9u/ml. There was a significant difference between the two (P<0.05). The comparison of CA15-3 values before and after surgery for breast cancer with CA15-3 values of axillary lymph node metastases before operation and found significant differences (P<0.05). Conclusion: CA15-3 has clinical application value in the diagnosis, metastasis, therapeutic judgment and monitoring of recurrence of breast cancer.